Fresenius acquired mAbxience stake. Fresenius stock gains 1.60 percent

Published on 10/09/2026 at 12:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached EUR 5.864 billion, up 6.00 percent year over year. Fresenius stock costs EUR 42.50 on October 9, 2026 after EUR 41.83.

Key points in brief

Fresenius acquired the remaining 45.00 percent of mAbxience for up to EUR 750.00 million on October 1, 2026.
Second-quarter 2026 revenue reached EUR 5.864 billion, up 6.00 percent year over year, while core net income rose 14.00 percent to EUR 470.00 million.
Fresenius stock was trading at EUR 42.50 at Lang & Schwarz on October 9, 2026, up 1.60 percent versus the EUR 41.83 prior close.
Jefferies kept a Buy rating and a EUR 55.00 target, while UBS maintained Buy with a EUR 56.00 target.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius acquired the remaining 45.00 percent of mAbxience for total consideration of up to EUR 750.00 million on October 1, 2026, including a contingent EUR 50.00 million payment tied to site approvals, according to Fresenius. Fresenius stock was trading at EUR 42.50 at Lang & Schwarz on October 9, 2026 at 12:05 p.m. CEST, up 1.60 percent versus the prior close of EUR 41.83.

Three strategic steps in 2026

On July 13, 2026, Fresenius issued EUR 1.00 billion in bonds, according to Fresenius. On September 9, 2026, the company said 1,700 of more than 4,000 Fresenius Health Services employees would transfer to Helios from January 1, 2027, according to Fresenius. The October 1 mAbxience transaction is the latest of the three steps and gives Fresenius full ownership of its biosimilars platform, according to Fresenius.

What does the deal mean for valuation?

Jefferies kept a Buy rating and a EUR 55.00 price target in its October 2, 2026 research note, as reported by FinanzNachrichten. The target lies 29.41 percent above the Lang & Schwarz price of EUR 42.50, while UBS maintained Buy with a EUR 56.00 target on September 16, 2026, according to MarketScreener.

Q2 earnings show operating progress

Fresenius reported EUR 5.864 billion in revenue for the second quarter of 2026, up 6.00 percent from EUR 5.571 billion in the second quarter of 2025, according to Fresenius. Group EBIT rose 10.00 percent year over year to EUR 719.00 million from EUR 654.00 million, while core net income increased 14.00 percent to EUR 470.00 million from EUR 412.00 million.

The reported figures are before special items, and the core net income measure excludes Fresenius Medical Care and Vitrea, according to Fresenius. That combination gives the mAbxience deal a stronger operating backdrop than the acquisition figure alone suggests, because revenue and core earnings were both higher than in the prior-year quarter.

Next scheduled reporting date

Fresenius lists its third-quarter 2026 conference call for November 4, 2026, according to Fresenius. The date gives investors the next scheduled point for testing whether the biosimilars strategy and the broader earnings improvement are translating into the company outlook.

Fresenius stock holds a positive session

Fresenius was trading at EUR 42.50 at Lang & Schwarz on October 9, 2026 at 12:05 p.m. CEST, up 1.60 percent versus the EUR 41.83 prior close at Lang & Schwarz. The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.